Paper38487532
The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
Deng W and 2 others. Front Immunol, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report. Papers, record 38487532. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38487532
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lung Neoplasms | Major topic |
| Asthma | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Indoles | Major topic |
| Quinolines | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Female | |
| Humans | |
| Middle Aged | |
| Combined Modality Therapy | |
| Immune Checkpoint Inhibitors | |
| Tumor Microenvironment |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28953502 | Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model. | Int J Gynecol Cancer | 2018 | https://conductscience.org/library/papers/28953502 | PubMed |
| 2 | 29656747 | Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. | Lung Cancer | 2018 | https://conductscience.org/library/papers/29656747 | PubMed |
| 3 | 34395243 | Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer. | Front Oncol | 2021 | https://conductscience.org/library/papers/34395243 | PubMed |
| 4 | 31616186 | Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. | Cancer Manag Res | 2019 | https://conductscience.org/library/papers/31616186 | PubMed |
| 5 | 33916438 | Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33916438 | PubMed |
| 6 | 11444391 | VEGF as a mediator of tumor-associated immunodeficiency. | Immunol Res | 2001 | https://conductscience.org/library/papers/11444391 | PubMed |
| 7 | 28945837 | Nivolumab-induced asthma in a patient with non-small-cell lung cancer. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28945837 | PubMed |
| 8 | 32983126 | Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. | Front Immunol | 2020 | https://conductscience.org/library/papers/32983126 | PubMed |
| 9 | 22855687 | Therapeutical measures to control airway tolerance in asthma and lung cancer. | Front Immunol | 2012 | https://conductscience.org/library/papers/22855687 | PubMed |
| 10 | 30178633 | Regulatory T cells and asthma. | J Zhejiang Univ Sci B | 2018 | https://conductscience.org/library/papers/30178633 | PubMed |
| 11 | 28865147 | Differential regulation of PD-1 and its ligands in allergic asthma. | Clin Exp Allergy | 2017 | https://conductscience.org/library/papers/28865147 | PubMed |
| 12 | 29654146 | Role of PD-1 during effector CD8 T cell differentiation. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29654146 | PubMed |
| 13 | 31078775 | Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. | J Thorac Oncol | 2019 | https://conductscience.org/library/papers/31078775 | PubMed |
| 14 | 34570052 | Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy. | J Immunother | 2022 | https://conductscience.org/library/papers/34570052 | PubMed |
| 15 | 32197856 | Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes. | Clin Lung Cancer | 2020 | https://conductscience.org/library/papers/32197856 | PubMed |
| 16 | 29774034 | Targeting VEGF/VEGFR to Modulate Antitumor Immunity. | Front Immunol | 2018 | https://conductscience.org/library/papers/29774034 | PubMed |
| 17 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 18 | 11015443 | Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. | J Exp Med | 2000 | https://conductscience.org/library/papers/11015443 | PubMed |
| 19 | 24263240 | Neuropilin 1: function and therapeutic potential in cancer. | Cancer Immunol Immunother | 2014 | https://conductscience.org/library/papers/24263240 | PubMed |
| 20 | 31046803 | Emerging therapies for small cell lung cancer. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31046803 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40803852 | Clinical and Pathophysiological Characteristics of Patients in Whom Asthma Developed during Treatment with Immune Checkpoint Inhibitors: A Retrospective Single-center Study. | Intern Med | 2026 | https://conductscience.org/library/papers/40803852 | PubMed |
| 40766328 | Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review. | Front Immunol | 2025 | https://conductscience.org/library/papers/40766328 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38487532
GET https://conductscience.org/api/papers/v1/38487532/references?page=2